Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting
for> 6 weeks with onset before 16 years of age. JIA is the most common chronic …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …

Objective To develop treatment recommendations for children with juvenile idiopathic
arthritis manifesting as non‐systemic polyarthritis, sacroiliitis, or enthesitis. Methods The …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Background Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody,
is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic
arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human …

Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis
of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have …

Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group
of arthritides of unknown cause, which begin before 16 years of age. This term …

Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth …